GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » EV-to-EBITDA

LakeShore Biopharma Co (LakeShore Biopharma Co) EV-to-EBITDA : -6.28 (As of May. 31, 2024)


View and export this data going back to 2023. Start your Free Trial

What is LakeShore Biopharma Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, LakeShore Biopharma Co's enterprise value is $210.82 Mil. LakeShore Biopharma Co's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-33.57 Mil. Therefore, LakeShore Biopharma Co's EV-to-EBITDA for today is -6.28.

The historical rank and industry rank for LakeShore Biopharma Co's EV-to-EBITDA or its related term are showing as below:

LSB' s EV-to-EBITDA Range Over the Past 10 Years
Min: -89.88   Med: -8.95   Max: -4.76
Current: -6.28

During the past 3 years, the highest EV-to-EBITDA of LakeShore Biopharma Co was -4.76. The lowest was -89.88. And the median was -8.95.

LSB's EV-to-EBITDA is ranked worse than
100% of 453 companies
in the Biotechnology industry
Industry Median: 9.26 vs LSB: -6.28

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-31), LakeShore Biopharma Co's stock price is $0.835. LakeShore Biopharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.569. Therefore, LakeShore Biopharma Co's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


LakeShore Biopharma Co EV-to-EBITDA Historical Data

The historical data trend for LakeShore Biopharma Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LakeShore Biopharma Co EV-to-EBITDA Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23
EV-to-EBITDA
- - -15.03

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
EV-to-EBITDA Get a 7-Day Free Trial - - - -15.03 -

Competitive Comparison of LakeShore Biopharma Co's EV-to-EBITDA

For the Biotechnology subindustry, LakeShore Biopharma Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LakeShore Biopharma Co's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where LakeShore Biopharma Co's EV-to-EBITDA falls into.



LakeShore Biopharma Co EV-to-EBITDA Calculation

LakeShore Biopharma Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=210.818/-33.571
=-6.28

LakeShore Biopharma Co's current Enterprise Value is $210.82 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. LakeShore Biopharma Co's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-33.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LakeShore Biopharma Co  (NAS:LSB) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

LakeShore Biopharma Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.835/-0.569
=At Loss

LakeShore Biopharma Co's share price for today is $0.835.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. LakeShore Biopharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.569.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


LakeShore Biopharma Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of LakeShore Biopharma Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


LakeShore Biopharma Co (LakeShore Biopharma Co) Business Description

Traded in Other Exchanges
Address
38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminium-free lyophilized rabies vaccine that was launched in China. It has one operating segment, which is the development, production, marketing and sale of biopharmaceutical products.